AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01973816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;
Description: Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
Study NCT01973816 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: rectal shaving; rectal disc excision; colorectal resection
Study NCT01973816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 50 mg; estradiol 0.5% percutaneous
Description: Daily intake for 18 months
Study NCT01973816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral
Description: Daily intake during 24 months
Study NCT02674165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HART
Description: Skills based sexual education intervention plus PTSD awareness
Study NCT01229891 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: plain yogurt drink
Description: daily intake of two bottle of plain yogurt drink
Study NCT03516214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGF816
Description: Continuous oral treatment (once daily) with the 3rd generation EGFR inhibitor EGF816.
Study NCT03516214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Continuous oral treatment (once daily) with the MEK inhibitor trametinib.
Study NCT02606214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TBA-354
Study NCT01229891 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D fortified yogurt drink
Description: daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
Study NCT01229891 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D-calcium yogurt drink
Description: daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
Study NCT01544686 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV
Description: Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
Study NCT01544686 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: 3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV
Description: Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
Study NCT00940524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib, Mitoxantrone, Cytarabine
Description: INDUCTION- Dasatinib† (dose levels 1-3) \*continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC > 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4~CONSOLIDATION A-Dasatinib† (dose levels 1-3) \*continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29
Study NCT01062087 — intervention group
Intervention type: DRUG
Intervention: Bupivacaine, Lidocaine
Description: Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
Study NCT02013128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Ublituximab (IV infusion)
Study NCT02013128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib oral daily dose
Study NCT03051828 — intervention group
Intervention type: PROCEDURE
Intervention: fencing
Description: No intervention: practice fencing
Study NCT03728504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN002
Description: Daily dose of ASN002 for 32 weeks
Study NCT03728504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Daily dose of Placebo Oral Tablet for 16 weeks
Study NCT04675606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Regular diet
Description: Patients in the regular diet arm (which is the experimental arm) will not have any diet limitations and will be recommended to consume a healthy balanced diet for American adults as recommended by the United States Department of Agriculture (USDA) and US Food and Drug Administration (FDA).
Study NCT04675606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low fiber diet
Description: Patients in the low fiber diet arm (which is the control arm) will be recommended to consume foods that are low in fiber content per United Ostomy Associations of America Recommendations
Study NCT00282568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus Modified Release (MR)
Description: Oral
Study NCT00282568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral
Study NCT04268095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dressing protocol
Description: Patients are assigned with different postoperative dressing protocols.
Study NCT00963404 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation boost
Description: Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
Study NCT01266122 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention
Description: The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
Study NCT03756571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle Foot Orthoses-Footwear Combination
Description: This is a solid AFO with angle of ankle in AFO and shoe modifications per algorithm based on physical exam and visual observation of lower extremity kinematics through stance phase of walking.
Study NCT02671461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986141
Study NCT02671461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study NCT02671461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Study NCT02671461 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02261883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Remodulin
Description: Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
Study NCT02261883 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium citrate, sodium chloride, sodium hydroxide pellets, metacresol, and citric acid (anhydrous).
Study NCT04169854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 5% patch
Description: The Lidocaine 5% Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
Study NCT04169854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: The Placebo Patch will be applied to cover the marked incision site and head-holders sites for 3 consecutive preoperative days between 6:00 P.M. to 6:00 A.M.. Research assistants will be responsible for instructing patients to cover the patches correctly.
Study NCT02881879 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allergovac depot DPT/DF (50:50)
Description: Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
Study NCT02229110 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Signal
Description: Automatic signal in the electronic medical record
Study NCT01412060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo was supplied in capsules.
Study NCT01412060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
Study NCT02963415 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Participants will take part in the exergame, 3 times a week for a month. The session will start for 30-35 minutes of cycling on recumbent stationary cycles in session 1 and progress to moderate intensity for 50 minutes a session. Participants will do warm-up and cool-down activities before and after cycling. While cycling, participants will be playing virtual reality based games. An exercise interventionist will supervise the sessions and monitor participant's conditions and responses to ensure safety.
Study NCT00168064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mechlorethamine-MCH (nitrogen mustard)
Description: All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
Study NCT05267197 — intervention group
Intervention type: OTHER
Intervention: 3D Telemedicine
Description: 3D Telemedicine system
Study NCT05267197 — intervention group
Intervention type: OTHER
Intervention: 2D Telemedicine
Description: 2D Telemedicine system
Study NCT01159509 — intervention group
Intervention type: BEHAVIORAL
Intervention: sodium taste tests
Description: The cohort group will had sodium taste tests and an interview regarding diat habits.
Study NCT00423241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SEMPERFLO Pain Management System
Description: continuous infusion of 0.5% bupivacaine at 2mL per hour
Study NCT00423241 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ON-Q PainBuster Post-Op Pain Relief System
Description: continuous infusion of 0.5% bupivacaine at 2mL per hour
Study NCT01179347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium Respimat® inhaler
Description: to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
Study NCT01179347 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Respimat® inhaler
Description: patient to receive placebo matching active drug once daily
Study NCT02986919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-0610
Description: * Optional tumor biopsy will be obtained prior to Day 1 of CPI-0610 administration.~* CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break. The 14 days of CPI-0610 dosing and the 7-day break together constitute 1 cycle of treatment. The dose will not be adjusted for body weight or body surface area.
Study NCT03756571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Solid Ankle AFO (TSAFO)
Description: This is a solid ankle AFO with angle of ankle in AFO at 90 degrees or neutral dorsiflexion/plantarflexion.
Study NCT01902784 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Storytelling Interview
Study NCT03480958 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intravenous morphine patient controlled device
Description: 24 hour morphine consumption will be recorded
Study NCT03480958 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine patient controlled device
Description: 24 hour morphine consumption will be recorded
Study NCT03480958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: erector spinae plane block will be administered before the surgery
Study NCT03480958 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: thoracic paravertebral block will be administered before the surgery
Study NCT02272283 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation
Description: The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
Study NCT02272283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation
Description: The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
Study NCT00051129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate 15 mg sterile suspension
Description: 0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
Study NCT00051129 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anecortave Acetate Vehicle
Description: Administered as a posterior juxtascleral injection
Study NCT01566201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anakinra
Description: Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
Study NCT01566201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: water for injection
Study NCT00691093 — intervention group
Intervention type: DRUG
Intervention: fesoterodine
Description: 4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
Study NCT02850744 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PQR309
Description: 80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
Study NCT02118064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G17DT-Irinotecan
Description: 500µg dose of G17DT intramuscular injection in combination with 125 mg/m\^2 intravenous infusion of Irinotecan over 90 minutes.
Study NCT00529516 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix
Description: Single dose, Intramuscular injection
Study NCT00529516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals Influenza Vaccine GSK576389A
Description: Single dose, Intramuscular injection
Study NCT02060955 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALECSAT
Description: The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
Study NCT02060955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab/Irinotecan
Description: Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
Study NCT01331720 — intervention group
Intervention type: DRUG
Intervention: hMG-HP
Study NCT02241928 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell
Description: Intrathecal Autologous bone marrow mononuclear cell transplantation
Study NCT00684112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
Study NCT00684112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
Study NCT01429610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab+mVPDL
Description: 1. Induction:~   * Dauno 90 mg/m2/d by civ (d1-3)~  * Vinc 2 mg iv (d1, 8)~  * Pred 60 mg/m2/d po (d1-14)~  * for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)~  * Rituximab 375mg/m2/d (d8)~2. Consolidation A (cycle1)~   * D 45 mg/m2/day by continuous iv (d1, 2)~  * V 2 mg iv (d1, 8)~  * P 60 mg/m2/day po (d1-14)~  * for Ph(-): L-asp (d1-14) for Ph(+): Imatinib~  * Rituximab 375mg/m2/d (d8)~3. Consolidation B (cycles2\&4)~   * Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)~  * Eto 150 mg/m2/d iv over 3 hr (d1-4)~  * Rituximab 375mg/m2/d d8~4. Consolidation C (cycles 3\&5)~   * Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)~  * Leucovorin 50 mg/m2 iv every 6hr for 3 doses,~  * Rituximab 375mg/m2/d (d8\&22)~5. Maintenance (for 2 years)~   - for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd~6. Consider alloHCT
Study NCT01896856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110 Dose Escalation
Description: * Dose level 1 (DL1): 45 mg/m\^2 administered as a subcutaneous injection~* Dose level 1G (DL1G): 45 mg/m\^2 administered as a subcutaneous injection + growth factor support~* Dose level -1 (DL-1): 30 mg/m\^2 administered as a subcutaneous injection~* Dose level -1G (DL-1G): 30 mg/m\^2 administered as a subcutaneous injection + growth factor support
Study NCT01896856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: 160 mg taken orally
Study NCT01896856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAS-102
Description: 35 mg/m\^2 taken orally
Study NCT01896856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGI-110
Description: 45 mg/m\^2 administered as a subcutaneous injection
Study NCT01896856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGI-110
Description: 45 mg/m\^2 administered as a subcutaneous injection
Study NCT01896856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 125 mg/m\^2 administered IV
Study NCT01896856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 125 mg/m\^2 administered IV
Study NCT02402712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
Study NCT02402712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pertuzumab [Perjeta]
Description: Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
Study NCT02402712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab [Herceptin]
Description: Subcutaneous administration of 600 mg/5 mL every 3 weeks
Study NCT02330107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MAT & LAT
Description: For MAT, the magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear.
Study NCT02330107 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: MAT & LAT
Description: For MAT, the magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.~For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear.
Study NCT03852121 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bibliotherapy
Description: Bibliotherapy is the use of reading materials for therapeutic benefits. In this study, an evidence-based modified manual will be used as the reading material. The manual adopts the self-directed problem-solving approach to dementia caregiving, examples of how other caregivers solve the specific problem for each chapter is included in the corresponding chapter. Bibliotherapy also involves guided learning by reading written information, enabling caregivers to solve their caregiving problems step-by-step, so telephone coach is designed to figure out participants understanding, find out the unsolved problems and guide them for finding out the solution by themselves.
Study NCT02715999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum Block
Description: After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
Study NCT02715999 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominis Plane Block
Description: After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.